PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress
Open accessPublished version of a preprint
The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index; 69 of the 82 sources its claims cite were checked for support.
Abstract
Hematopoietic stem cells (HSCs) are capable of entering the cell cycle to replenish the blood system in response to inflammatory cues; however, excessive proliferation in response to chronic inflammation can lead to either HSC attrition or expansion. The mechanism(s) that limit HSC proliferation and expansion triggered by inflammatory signals are poorly defined. Here, we show that long-term HSCs (HSCLT) rapidly repress protein synthesis and cell cycle genes following treatment with the proinflammatory cytokine interleukin (IL)-1. This gene program is associated with activation of the transcription factor PU.1 and direct PU.1 binding at repressed target genes. Notably, PU.1 is required to repress cell cycle and protein synthesis genes, and IL-1 exposure triggers aberrant protein synthesis and cell cycle activity in PU.1-deficient HSCs. These features are associated with expansion of phenotypic PU.1-deficient HSCs. Thus, we identify a PU.1-dependent mechanism triggered by innate immune stimulation that limits HSC proliferation and pool size. These findings provide insight into how HSCs maintain homeostasis during inflammatory stress.
Overview
CoChat Summary
TL;DR
Chavez et al. show that chronic IL-1 represses cell cycle and protein synthesis genes in long-term hematopoietic stem cells (HSCLT), and that the myeloid transcription factor PU.1 directly binds and enforces this quiescent program. PU.1 deficiency derepresses these genes, allowing IL-1 to drive aberrant protein synthesis, cell cycle entry, and expansion of the phenotypic HSCLT pool.
Key findings
- Chronic IL-1β treatment for 20 d induced >1,400 differentially expressed genes (Padj < 0.05) in SLAM HSCs, with downregulated genes enriched for ribosome biogenesis, rRNA processing, tRNA processing, translation, and cell proliferation pathways; HSCLT remained largely quiescent and showed homeostatic protein synthesis rates despite gene repression.
- PU.1 ChIP-seq in HSC-enriched LSK/Flk2−/CD150+ cells identified 52,127 unique PU.1 peaks, and most IL-1 DEGs had PU.1 peaks within ±20 kb of the TSS (586/694 IL-1–up genes; 599/771 IL-1–down genes), including Myc.
- PU.1KI/KI mice, expressing ∼30% of normal PU.1 in SLAM cells, showed derepression of cell cycle and protein synthesis genes in HSCLT; chronic IL-1 further increased these genes and triggered exuberant protein synthesis, increased cell cycle activity, and expansion of phenotypic HSCLT in bone marrow and spleen.
- In vitro, IL-1 delayed HSCLT division and increased PU.1-EYFP before first division; PU.1 activation via PU.1-ERT similarly delayed division, and the translation inhibitor omacetaxine phenocopied IL-1 by limiting HSCLT cell cycle entry.
Methods
- Mouse models: C57BL/6, PU.1KI/KI, PU.1flox/SCL-CreERT, PU.1-EYFP, GFP-Myc, PU.1-ERT, and H2B-GFP reporter mice; IL-1β was injected i.p. at 0.5 µg daily for 1 or 20 d.
- HSC-enriched SLAM (LSK/Flk2−CD48−CD150+) and HSCLT (LSK/Flk2−CD48−CD150+CD34−EPCR+) populations were analyzed by flow cytometry, cell cycle/Ki-67/DAPI, intracellular Myc and puromycin staining, Fluidigm qRT-PCR, RNA-seq, ChIP-seq, single-cell time-lapse imaging, and in vitro culture with IL-1β, 4-OHT, or omacetaxine.
- RNA-seq differential expression used DESeq2 (Padj < 0.05); ChIP-seq used HOMER peak calling; GSEA, IPA, and GO analyses were performed on DEGs and PU.1-bound gene sets.
Limitations
- The paper states that direct versus indirect effects of IL-1 on HSCLT proliferation in vivo remain to be clarified with bone marrow chimera models, and that future studies are needed to identify which signaling pathways trigger aberrant protein synthesis and cell cycle activity in PU.1-deficient HSCs.
- The paper notes that despite IL-1–mediated repression of protein synthesis genes and slowed in vitro cell cycle progression, protein synthesis rates were not decreased in IL-1–exposed HSCLT in vivo, suggesting the repression may dampen mitogenic signaling rather than block translation outright.
- Evident from the text: most mechanistic evidence comes from mouse models and in vitro culture, with limited human validation; the study also relies heavily on phenotypic HSCLT fractions and reporter mice, and some key experiments use small replicate numbers (e.g., n = 2–3/group in some ChIP-seq or conditional knockout analyses).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 4. Direct IL-1 stimulation in vitro induces PU.1 and restricts HSCLT cell cycle entry. (A) Representative FACS plots (left) and quantification (right) of cell cycle distribution in HSCLT cultured for 24 h with or without IL-1β (n = 6/group). Data are compiled from three independent experiments. (B) Experimental design for single-cell tracking studies of PU.1-EYFP HSCLT cultured with or without IL-1β. Time to first cell division was tracked via microscopy. (C) Graph showing kinetics of first cell division in HSCLT from B (n = 194 −IL-1β; 139 IL-1β). Data are compiled from three independent experiments. (D) PU.1-EYFP levels in HSCLT before first cell division (n = 137 −IL-1β; 192 +IL-1β). Data are compiled from three independent experiments. Box shows upper and lower quartiles with line showing median value, and whiskers upper and lower 10th percentile and individual dots represent outliers. (E) Hierarchical clustering analysis of PU.1-EYFP expression over time from the start of observation until the first division in PU.1-EYFP HSCLT cultured with or without IL-1 (Euclidean distance with Ward linkage; n = 557 −IL-1β; 489 +IL-1β). Data are compiled from three independent experiments. (F) Quantification of PU.1-EYFP level (as arbitrary units [AU]; left) and time to division (right) of HSCLT cultured with or without IL-1β in E. Individual values (representing means from cells cultured either with or without IL-1β in an experiment) are shown with bars representing mean values (n = 6). Data are compiled from three independent experiments. (G) Distribution of HSCLT from E in different clusters based on culture with or without IL-1β. Data are compiled from three independent experiments. (H) Experimental design for Fluidigm qRT-PCR array analysis of HSCLT cultured with or without IL-1β for 12 h. (I) Quantification by Fluidigm qRT-PCR array of cell cycle and protein synthesis gene expression in HSCLT from F (n = 8/group). Data are expressed as log10 fold expression versus −IL-1β. Box represents upper and lower quartiles with line representing median value. Whiskers represent minimum and maximum values. Data are representative of two independent experiments. (J) Experimental design for cell cycle analysis of HSCLT cultured with or without IL-1β and with or without 100 nM Oma for 24 h. (K) Representative FACS plots (left) and quantification (right) of cell cycle distribution in HSCLT from H (n = 3/group). Data are from one experiment. (L) Proportion of HSCLT with >2N DAPI signal from H. Individual values are shown with means (horizontal line). *, P < 0.05; **, P < 0.01; ***, P < 0.001 by Mann-Whitney U test or one-way ANOVA with Tukey’s test in F, G, K, and L. Error bars represent SD. See also Fig. S3.](https://figures.cochat.ai/paper-figures/3283b30cd4854603acf61aaaae485d40/pu-1-enforces-quiescence-and-limits-hematopoietic-stem-cell-expansion-during-figure-4.jpg)






Verification
Claims the paper makes
46 Valid · 1 Not valid · 3 Not checked · 122 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with prior work (Signer et al., 2014), puro incorporation rates in HSCLT, SLAM cells, and MPP4 were all similar (Fig. S1 G)”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Results > Chronic IL-1 induces repression of cell cycle and protein synthesis genes in long-term HSCs (HSCLT)
What the sources say
- Partly supportedcites Signer et al., 2014 matched to “Haematopoietic stem cells require a highly regulated protein synthesis rate” (2014) sourceExperimental — accuracy not yet measured
In “HSCs synthesize less protein per hour” (page unavailable), the paper reports similar OP-Puro incorporation in CD150−CD48−LSK MPPs and CD150+CD48−LSK HSCs. It does not separately report incorporation rates for the specifically named HSCLT, SLAM, and MPP4 populations, so it supports the general comparison but not the claim at that level of specificity. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Interestingly, activation of this gene program relies, at least in part, on IL-1 signaling (Hernandez et al., 2020).”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Introduction
What the sources say
- Partly supportedcites Hernandez et al., 2020 matched to “Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis” (2020) sourceExperimental — accuracy not yet measured
The Results section on cytokine blockade (page unavailable) reports that the IL-1 receptor blocker anakinra partially normalized expression of proliferation-arrest genes in HSC from mice with collagen-induced arthritis. This supports a possible contribution from IL-1 signaling, but the paper does not establish that activation of the program relies on it: HSC cell-cycle distribution was unchanged, and the Discussion says anakinra’s effects could be indirect. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Previous work from our group demonstrates that acute IL-1 exposure drives myeloid cell overproduction in vivo via precocious activation of the master myeloid transcription factor PU.1 (Pietras et al., 2016) in HSC.”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Introduction
What the sources say
- Supportedcites Pietras et al., 2016 matched to “Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal” (2016) source
The Results section, “Haematopoietic remodelling following IL-1 exposure” (page not provided), says that in vivo IL-1 exposure rapidly activates a PU.1-mediated myeloid differentiation program in HSCs and amplifies myeloid cell production. The Results section, “Precocious activation of a PU.1 molecular circuit” (page not provided), also reports rapid PU.1 activation after IL-1 exposure and its role in accelerated myeloid differentiation. (LLM, conf=0.92)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We recently found that quiescent HSCs downregulate numerous protein synthesis and cell proliferation genes in a mouse model of chronic rheumatoid arthritis (Hernandez et al., 2020).”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Introduction
What the sources say
- Supportedcites Hernandez et al., 2020 matched to “Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis” (2020) source
The Results section (page not provided) reports that HSCs from mice with collagen-induced arthritis retained a quiescent phenotype. It also reports downregulated genes involved in protein translation and cell-cycle progression, matching the claim. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings imply the existence of a braking mechanism that limits HSC cell cycle entry in response to chronic inflammatory stress (Pietras et al., 2016; Rabe et al., 2020).”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Introduction
What the sources say
- Partly supportedcites Pietras et al., 2016 matched to “Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal” (2016) sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that the HSC pool remains intact after chronic IL-1 exposure and suggests that a quiescent HSC subset may replenish responsive cells. That provides a basis for the citing authors’ inference, but the paper does not identify a braking mechanism limiting cell-cycle entry; the Results instead report increased HSC division after IL-1 treatment. (LLM, conf=0.80)
- Supportedcites Rabe et al., 2020 matched to “CD34 and EPCR coordinately enrich functional murine hematopoietic stem cells under normal and inflammatory conditions” (2020) source
In Results (‘The EPCR+/CD34− SLAM fraction remains quiescent following chronic IL-1 exposure’; page not provided), the paper reports minimal cell-cycle induction during chronic IL-1 exposure and suggests an Rb-mediated ‘braking’ mechanism in two EPCR− fractions. It also reports reduced expression of genes crucial for HSC cell-cycle entry in the EPCR+/CD34− fraction. The claim appropriately frames a braking mechanism as an implication, rather than an established cause. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
101 more claims · 13 with their cited sources checked
Create a free account to see all 172 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 43
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PU.1 has also been identified as a master regulator in HSC cell fate decisions and homing through the interaction with a variety of regulatory factors.34,35”
From PELI2 regulates early B-cell progenitor differentiation and related leukemia via the IL-7R expression (2023) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, IL-1 can stimulate HSC proliferation, driving their myeloid differentiation at the expense of self-renewal, thus eroding their repopulating capacity.28,49,50”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In phenotypically defined long-term HSC, increased PU.1 levels drive 1) activation of myeloid differentiation gene programs and 2) repression of cell proliferation (Chavez et al., 2021), thereby limiting the expansion of the HSC pool.”
From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Chavez et al., 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“PU.1 maintains HSC quiescence during inflammatory stress by limiting protein production and suppressing cell cycle progression, thus preventing excessive HSC proliferation 20.”
From USP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization (2026) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“We previously showed that PU.1 deficiency leads to increased proliferation in HSCLT following IL-1β stimulation, thereby driving expansion of these cells in vivo (Chavez et al., 2021).”
From PU.1 is required to restrain myelopoiesis during chronic inflammatory stress (2023) · cites this paper as Chavez et al., 2021
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Results > Direct IL-1 stimulation in vitro induces PU.1 and restricts HSCLT cell cycle entry
“(K) Representative FACS plots (left) and quantification (right) of cell cycle distribution in HSCLT from H (n = 3/group). Data are from one experiment. (L) Proportion of HSCLT with >2N DAPI signal from H.”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Results > Direct IL-1 stimulation in vitro induces PU.1 and restricts HSCLT cell cycle entry
“(J) Experimental design for cell cycle analysis of HSCLT cultured with or without IL-1β and with or without 100 nM Oma for 24 h.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Results > IL-1–induced gene repression is associated with increased PU.1 levels
“(I) Representative FACS plots (left) and quantification (right) showing GFP-Myc expression levels in PU.1lo and PU.1hi SLAM cell fractions from mice in C.”
§ PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress > Results > IL-1–induced gene repression is associated with increased PU.1 levels
“As predicted by our data, phenotypic HSCLT expressed elevated levels of PU.1-EYFP, whereas GFP-Myc levels were reduced (Fig. 3, H and I).”
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · cited 1×
“Fastq read files were trimmed using Cutadapt (Martin, 2011).”
MethodGraph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Kim, D., Paggi, J. M., Park, C., Bennett, C., & Salzberg, S. L. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0201-4 · Cited by 15,022 · cited 1×
“The trimmed reads were mapped to mm10 mouse genome using HISAT2 (Kim et al., 2019).”
MethodHeinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382 · cited 3×
“S4F) at different timepoints post induction (Heinz et al., 2010).”
BackgroundMethodInfluentialMetsalu, T., & Vilo, J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv468 · Cited by 3,709 · cited 1×
“ee/clustvis) (Metsalu and Vilo, 2015).”
InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams
Heberle, H., Meirelles, G. V., da Silva, F. R., Telles, G. P., & Minghim, R. (2015) · BMC Bioinformatics · doi:10.1186/s12859-015-0611-3 · Cited by 2,580
The bone marrow niche for haematopoietic stem cells
Morrison, S. J., & Scadden, D. T. (2014) · Nature · doi:10.1038/nature12984 · Cited by 2,451 · cited 1×
“, 2020), and signals generated from the bone marrow (BM) niche (Morrison and Scadden, 2014).”
BackgroundWilson, A., Laurenti, E., Oser, G., van der Wath, R. C., Blanco-Bose, W., Jaworski, M., Offner, S., Dunant, C. F., Eshkind, L., Bockamp, E., et al. (2008) · Cell · doi:10.1016/j.cell.2008.10.048 · Cited by 1,908 · cited 3×
“…capacity even under a variety of inflammatory stress conditions (Bujanover et al., 2018; Hernandez et al., 2020; Pietras et al., 2014; Pietras et al., 2016; Rabe et al., 2020; Wilson et al., 2008; Zhao et al., 2019), implying the existence of mechanism(s) that prevent spurious HSC cell cycle entry.”
BackgroundOverview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866 · cited 3×
“IL-1 is produced in response to a wide variety of physiological stress conditions including aging, chronic inflammatory disease, myeloablative treatments such as radiation and/or chemotherapy, obesity and cellular senescence (Dinarello, 2018; Laberge et al., 2015).”
BackgroundInfluentialIFNα activates dormant haematopoietic stem cells in vivo
Essers, M. A. G., Offner, S., Blanco-Bose, W. E., Waibler, Z., Kalinke, U., Duchosal, M. A., & Trumpp, A. (2009) · Nature · doi:10.1038/nature07815 · Cited by 1,368
Cited by
Caiado, F., Pietras, E. M., & Manz, M. G. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201541 · Cited by 289
“1-deficient HSCs are largely insensitive to this effect of IL-1, fail to repress Myc, and instead continue to proliferate and expand in the BM (Chavez et al., 2021) during IL-1 exposure.”
BackgroundSelf-citationOu, X., Wang, H., Tie, H., Liao, J., Luo, Y., Huang, W., Yu, R., Song, L., & Zhu, J. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01919-x · Cited by 229
Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling
Caiado, F., Kovtonyuk, L. V., Gonullu, N. G., Fullin, J., Boettcher, S., & Manz, M. G. (2023) · Blood · doi:10.1182/blood.2022016835 · Cited by 161
Hematopoietic stem cells through the ages: A lifetime of adaptation to organismal demands
Kasbekar, M., Mitchell, C. A., Proven, M. A., & Passegué, E. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.09.013 · Cited by 132
Made to order: emergency myelopoiesis and demand-adapted innate immune cell production
Swann, J. W., Olson, O. C., & Passegue, E. A. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-00998-7 · Cited by 116
“In particular, IL-1 and IFNγ signalling drive clonal expansion of Tet2 -mutant and Dnmt3a -mutant HSCs, respectively, in murine models 179,181 .”
InfluentialAutophagy counters inflammation-driven glycolytic impairment in aging hematopoietic stem cells
Dellorusso, P. V., Proven, M. A., Calero‐Nieto, F. J., Wang, X., Mitchell, C. A., Hartmann, F. J., Amouzgar, M., Favaro, P. M. B., DeVilbiss, A., Swann, J. W., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.04.020 · Cited by 71
Inflammation, Aging and Hematopoiesis: A Complex Relationship
Bousounis, P., Bergo, V., & Trompouki, E. (2021) · Cells · doi:10.3390/cells10061386 · Cited by 67
“1 that directly binds and represses genes related to cycling and protein synthesis, thus safeguarding HSC functionality [57].”
BackgroundHiga, K. C., Goodspeed, A., Chavez, J. S., De Dominici, M., Danis, E., Zaberezhnyy, V., Rabe, J. L., Tenen, D. G., Pietras, E. M., & DeGregori, J. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200560 · Cited by 57
Self-citationInflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies
Camacho, V., Kuznetsova, V., & Welner, R. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772408 · Cited by 68
“Proinflammatory Mediator IL-1b IL-1 is a proinflammatory cytokine produced by myeloid cells and monocytes in response to infection and cellular stress and various investigations have uncovered the role of IL-1b in HSC and myeloid cell homeostasis (34, 35).”
BackgroundSelf-citationInflammation and Aging of Hematopoietic Stem Cells in Their Niche
Yang, D., & de Haan, G. (2021) · Cells · doi:10.3390/cells10081849 · Cited by 58
“IL1-β Monocytes, macrophages, ECs, Myeloid differentiationImpaired repopulation potential Up [3,4,36,42,82]”
BackgroundEndogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation
Villatoro, A., Cuminetti, V., Bernal, A., Torroja, C., Cossío, I., Benguría, A., Ferré, M., Konieczny, J., Vázquez, E., Rubio, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35700-9 · Cited by 59
Mills, T., Kain, B. N., Burchill, M. A., Danis, E. P., Lucas, E. D., Culp‐Hill, R., Cowan, C. M., Schleicher, W. E., Patel, S. B., Tran, B. T., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.09.010 · Cited by 57
Self-citationMolecular regulation of hematopoietic stem cell quiescence
Chen, Z., Guo, Q., Song, G., & Hou, Y. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04200-w · Cited by 60
Ageing, immune fitness and cancer
Dolan, M., Libby, K. A., Ringel, A. E., van Galen, P., & McAllister, S. S. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00858-z · Cited by 62
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
Kouroukli, O., Symeonidis, A. S., Foukas, P. G., Maragkou, M., & Kourea, E. P. (2022) · Cancers · doi:10.3390/cancers14225656 · Cited by 58
Open-source personal pipetting robots with live-cell incubation and microscopy compatibility
Dettinger, P., Kull, T., Arekatla, G., Ahmed, N., Zhang, Y., Schneiter, F., Wehling, A., Schirmacher, D., Kawamura, S., Loeffler, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30643-7 · Cited by 40
Self-citationIL-1 in aging and pathologies of hematopoietic stem cells
Caiado, F., & Manz, M. G. (2024) · Blood · doi:10.1182/blood.2023023105 · Cited by 44
Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective
Si, X., Gu, T., Liu, L., Huang, Y., Han, Y., Qian, P., & Huang, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215920 · Cited by 36
Inflammageing and clonal haematopoiesis interplay and their impact on human disease
Hajishengallis, G., & Chavakis, T. (2026) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00936-y · Cited by 40
Chavez, F. H., Luo, H., Cifani, P., Pine, A., Chu, E. L., Joshi, S., Barin, E., Schurer, A., Chan, M., Chang, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38001-x · Cited by 25
EBF1 primes B-lymphoid enhancers and limits the myeloid bias in murine multipotent progenitors
Lenaerts, A., Kuciński, I., Deboutte, W., Derecka, M., Cauchy, P., Manke, T., Göttgens, B., & Grosschedl, R. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212437 · Cited by 26
“In addition to their role in the differentiation of intermediate progenitors, PU.1 and C/EBPα are also required to maintain HSC quiescence and self-renewal capacity (Iwasaki et al., 2005; Ye et al., 2013; Hasemann et al., 2014; Chavez et al., 2021).”
BackgroundCHIPing away the progression potential of CHIP: A new reality in the making
Xie, Z., & Zeidan, A. M. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101001 · Cited by 23
Venugopal, K., Feng, Y., Nowialis, P., Xu, H., Shabashvili, D. E., Berntsen, C. M., Kaur, P., Krajcik, K. I., Taragjini, C., Zaroogian, Z., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2863 · Cited by 26
Trino, S., Laurenzana, I., Lamorte, D., Calice, G., Stradis, A. D., Santodirocco, M., Sgambato, A., Caivano, A., & Luca, L. D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.824562 · Cited by 24
“Overall, we believe that AML cells, through EVs, induce HSPCs to release cytokines and grow factors which contribute to generate an inflammatory environment that drives leukemia (52, 53) and supports “leukemic-like” HSPC growth.”
BackgroundZhao, H., & Deininger, M. W. (2023) · Blood · doi:10.1182/blood.2022017152 · Cited by 23
Linking cell cycle to hematopoietic stem cell fate decisions
Treichel, S., & Filippi, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1231735 · Cited by 23
“Exposure to the proinflammatory cytokine interleukin (IL)-1 can repress cell cycle and protein synthesis genes to maintain HSC functions (Chavez et al., 2021).”
BackgroundBeyond “to divide or not to divide”: Kinetics matters in hematopoietic stem cells
Johnson, C., Belluschi, S., & Laurenti, E. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.003 · Cited by 18
Chronic inflammation can transform the fate of normal and mutant hematopoietic stem cells
Li, J., Malouf, C., Miles, L. A., Willis, M., Pietras, E. M., & King, K. Y. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.08.008 · Cited by 18
Self-citationFunction of hematopoiesis and bone marrow niche in inflammation and non-hematopoietic diseases
Wang, Y., Deng, Z., Li, Y.-Y., Bai, K., Ma, J., Liu, Y., & Chen, Q. (2025) · Life Medicine · doi:10.1093/lifemedi/lnaf015 · Cited by 21
“IL-1 β , a key mediator of innate immunity, directly influences HSPCs by promoting their proliferation and differentiation into myeloid lineages, primarily through the activation of the transcription factor PU.1 [147].”
Transcription factor networks in cellular quiescence
Mitra, M., Batista, S., & Coller, H. A. (2025) · Nature Cell Biology · doi:10.1038/s41556-024-01582-w · Cited by 21
“PU.1, a member of the E26 transformation-specific (ETS) TF family 53 , induces quiescence in HSCs by repressing the expression of genes regulated by the inflammation-associated cytokine interleukin-1, resulting in reduced protein synthesis and a slowed cell cycle 54 .”
Rajagopalan, A., Feng, Y., Gayatri, M. B., Ranheim, E. A., Klungness, T., Matson, D. R., Lee, M. H., Jung, M. M., Zhou, Y., Gao, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci173116 · Cited by 21
Chavez, J. S., Rabe, J. L., Hernandez, G., Mills, T., Niño, K. E., Davizon‐Castillo, P., & Pietras, E. M. (2022) · Cells · doi:10.3390/cells11040680 · Cited by 19
“We previously demonstrated that EPCR+/CD34− SLAM cells contain the majority of long-term HSC (HSCLT) activity, and these markers faithfully enrich for HSCLT within the SLAM compartment of IL-1β-treated mice [6,7].”
BackgroundMethodInfluentialSelf-citationPU.1 is required to restrain myelopoiesis during chronic inflammatory stress
Chavez, J. S., Rabe, J. L., Niño, K. E., Wells, H. H., Gessner, R. L., Mills, T. S., Hernandez, G., & Pietras, E. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1204160 · Cited by 14
“We recently showed that PU.1 also functions to prevent spurious HSC proliferation and expansion of the HSC pool during chronic inflammatory stress by repressing induction of cell proliferation gene programs during chronic IL-1β treatment (Chavez et al., 2021).”
BackgroundMethodInfluentialSelf-citationHoward, J. E., Smith, J. N. P., Fredman, G., & MacNamara, K. C. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.10.011 · Cited by 15
“HSCs can respond directly to inflammatory insults, such as infection, however, and IL-1R-dependent signals can activate LT-HSCs and reduce quiescence (Chavez et al., 2021).”
BackgroundStem cell–like reprogramming is required for leukemia-initiating activity in B-ALL
Fregona, V., Bayet, M., Bouttier, M., Largeaud, L., Hamelle, C., Jamrog, L. A., Prade, N., Lagarde, S., Hébrard, S., Luquet, I., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230279 · Cited by 12
“Thus, to further identify and characterize quiescent pre-LSCs, we generated PE tg :: H2B-GFP tg mice, derived from doxycycline-inducible H2B-GFP tg mice, an in vivo model allowing the study of cell quiescence in normal HSCs (Foudi et al., 2009; Wilson et al., 2008).”
BackgroundInfluentialANP32B suppresses B‐cell acute lymphoblastic leukemia through activation of PU .1 in mice
Yang, Q., Liu, H., Yang, S., Wei, Y., Zhu, X., Zhi, Z., Zhu, D., Chen, G., & Yu, Y. (2023) · Cancer Science · doi:10.1111/cas.15822 · Cited by 11
Ma, T., Liu, J., Gao, Z., Li, Y., Lin, J., Pang, K., Li, R. Q., Zhang, X., Tang, L., Liu, Y., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03589-y · Cited by 12
Myeloid cells promote interferon signaling-associated deterioration of the hematopoietic system
Feyen, J., Ping, Z., Chen, L., van Dijk, C., van Tienhoven, T. V. D., van Strien, P. M. H., Hoogenboezem, R. M., Wevers, M. J. W., Sanders, M. A., Touw, I. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35318-x · Cited by 11
Basal type I interferon signaling has only modest effects on neonatal and juvenile hematopoiesis
Li, Y., Yang, W., Wang, H. C., Patel, R. M., Casey, E. B., Denby, E., & Magee, J. A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008595 · Cited by 9
“Likewise, IL-1β exposure induces transient HSC proliferation and myelopoiesis.(5,8) These changes enhance blood production and immune function under conditions of stress.”
BackgroundXu, Y., Liu, X., Chen, H., Zhao, Y., Zhao, Y., Xie, Y., Pang, J., Zeng, H., Zeng, Y., Peng, W., et al. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-02089-x · Cited by 10
“…a key signaling mechanism in the regulation of NP. Spi1, a transcription factor member of the E26 trans-formation-specific family, is most highly expressed in peripheral myeloid cells and impacts the function of numerous immune cells in different physiological and pathological conditions [45, 46].”
Blood stem cell PU.1 upregulation is a consequence of differentiation without fast autoregulation
Ahmed, N., Etzrodt, M., Dettinger, P., Kull, T., Loeffler, D., Hoppe, P. S., Chavez, J. S., Zhang, Y., Camargo Ortega, G., Hilsenbeck, O., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20202490 · Cited by 9
“1 levels are crucial for normal hematopoiesis (Etzrodt et al., 2019; Hoppe et al., 2016; Kueh et al., 2013; Leddin et al., 2011; Pietras et al., 2016; Chavez et al., 2021; Nerlov and Graf, 1998; McIvor et al., 2003; Zhang et al., 2000; Staber et al., 2013; Scott et al., 1994; Rosenbauer et al., 2004).”
BackgroundResultSelf-citationTranscriptional activation of regenerative hematopoiesis via microenvironmental sensing
Itkin, T., Houghton, S., Schreiner, R. P., Lin, Y., Badwe, C. R., Voisin, V., Murison, A., Seyedhassantehrani, N., Kaufmann, K. B., García‐Prat, L., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02087-w · Cited by 11
“https://doi.org/10.1038/s41590-025-02087-w HSPCs 9 .”
InfluentialSelf-citationAberrant engagement of P-selectin drives hematopoietic stem cell aging in mice
Yang, D., Skinder, N., Kao, Y.-R., Chen, J., Thiruthuvanathan, V. J., Svendsen, A. F., Zhang, C., Dethmers-Ausema, B., Weersing, E., Maryanovich, M., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00880-8 · Cited by 11
“In accordance with previous We identified IL-1β as a key driver of Selp expression and P-selectin presentation in HSCs acutely challenged with the proinflammatory cytokine which unveiled a highly conserved mechanism of Selp regulation between endothelial cells and HSCs 41–44 .”
Obesity, bone marrow adiposity, and leukemia: Time to act
Kumar, V., & Stewart, J. H. (2023) · Obesity Reviews · doi:10.1111/obr.13674 · Cited by 9
“154,155 Dying adipocytes fuse with CD11c + pro-inflammatory macrophages and form macrophage syncytia, a hallmark of chronic inflammation.”
BackgroundExpansion of Quiescent Hematopoietic Stem Cells under Stress and Nonstress Conditions in Mice
Zhang, S., Ma, Y., Wang, L., Li, X., Dong, Y., Wang, J., Cheng, T., Dong, F., & Ema, H. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10380-6 · Cited by 10
“Quiescence also plays an essential role in reconstitution [22, 31, 32].”
BackgroundWang, H. C., Chen, R., Yang, W., Li, Y., Muthukumar, R., Patel, R. M., Casey, E. B., Denby, E., & Magee, J. A. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114542 · Cited by 7
“…responses may contribute to MDS/AML initiation in the setting of a KMT2C mutation: reduced IL-1 β and type I interferon sensitivity helps mitigate the loss of HSC self-renewal capacity after chemotherapy, 60–64 and G-CSF hypersensitivity helps amplify and mobilize the mutant HSC population.”
BackgroundHydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms
Castillo, S. C., Montibus, B., Rocha, A. V., Duke, W., von Meyenn, F., McLornan, D. P., Harrison, C. N., Mullally, A., Schulz, R., & Oakey, R. J. (2021) · Genome Research · doi:10.1101/gr.270066.120 · Cited by 8
“sion (Chavez et al. 2021), our findings present SPI1 as a potential target for myeloproliferative diseases.”
BackgroundWalking the Tightrope: Balancing Delicate Inflammation Response to Eradicate Acute Myeloid Leukemia
Puissant, A., & Medyouf, H. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0473 · Cited by 5
Zong, L., Park, B., Tekinturhan, F., Kuribayashi, W., Tanaka-Yano, M., Li, K., & Beerman, I. (2026) · Nature Communications · doi:10.1038/s41467-026-69718-0 · Cited by 4
Cell-intrinsic factors governing quiescence vis-à-vis activation of adult hematopoietic stem cells
Budgude, P., Vaidya, A., & Kale, V. P. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04594-y · Cited by 6
“1 protects HSCs’ functionality during chronic inflammatory stress by directly binding and repressing the genes involved in cycling and protein synthesis [45].”
BackgroundSun, T., Li, D., Huang, L., & Zhu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1141779 · Cited by 6
Insights Regarding the Role of Inflammasomes in Leukemia: What Do We Know?
Alves-Hanna, F. S., Crespo-Neto, J. A., Nogueira, G. M., Pereira, D. S., Lima, A. B., Pereira-Ribeiro, T. L., Santos, V. G. R., Fonseca, J. R. F., Magalhães-Gama, F., Sadahiro, A., et al. (2023) · Journal of Immunology Research · doi:10.1155/2023/5584492 · Cited by 6
Xu, Y., Zhou, Q., Wang, X., Zhang, A., Qi, W., Li, Y., Zheng, C., Guan, J., Sun, T., Li, J., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.284041 · Cited by 3
An inflammatory and quiescent HSC subpopulation expands with age in humans
Safina, K. R., Salik, B., Kotliar, D., Curtis, M. L., Good, J., Weng, C., David, S., Raychaudhuri, S., Kreso, A., Trowbridge, J. J., et al. (2026) · Genome biology · doi:10.1186/s13059-026-03936-z · Cited by 8
“In contrast, our data link inflammatory signaling and quiescence within a single program associated with aging, more reminiscent of chronic inflammation which can induce quiescence [30, 31].”
Reprogramming of 3D genome structure underlying HSPC development in zebrafish
He, M., Li, X., Xu, B., Lu, Y., Lai, J., Ling, Y., Liu, H., An, Z., Zhang, W., & Li, F. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03798-x · Cited by 4
“In addition, bone marrow HSCs disrupted with PU.1 in situ could not maintain hematopoiesis and were out-competed by normal HSCs. PU.1 also limits hematopoietic stem cell expansion and prevents exhaustion of adult HSPC [58].”
BackgroundUnderstanding MDS stem cells: Advances and limitations
Patel, S. B., Moskop, D. R., Jordan, C. T., & Pietras, E. M. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.09.007 · Cited by 3
Self-citationXuan, J., Liu, Y., Liu, J., Zeng, X., & Wang, H. (2022) · Life · doi:10.3390/life12050716 · Cited by 4
“A time-dependent activation can cause HSCs enrichment, but the over-activation of mTOR may lead to LSK senescence and not apoptosis [70].”
BackgroundUSP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization
Shan, H., Zhang, Y., Xiao, X., Wu, W., Wang, Y., Zhu, C., Bai, W., Zhang, Z., Zhai, Y., Yang, L., et al. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.123712 · Cited by 3
“Given that PU.1 is a critical determinant of HSC differentiation [19, 20] and considering the phenotypic parallels observed in both Pu.1 and Usp7 conditional knockout models (reduced quiescence and diminished repopulating capacity of HSCs), we examined whether PU.1 is regulated by USP7.”
Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia
Uible, E. E., Choi, I., Clough, C. A., Hassan, A., Anandappa, A. J., Fisher, J., Karki, B., Hueneman, K. M., Choi, K., Vick, E. J., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2025.12.002 · Cited by 2
“13 First, we confirmed that exogenous IL-1 β can activate NF-κ B in THP1 cells using cells expressing a destabilized GFP driven by an NF-κ B response element 43,44 (Figures 1I and S2L).”
Kalogeraki, M., Rondeau, V., Nader, Z. A., Espéli, M., & Balabanian, K. (2026) · iScience · doi:10.1016/j.isci.2026.114921 · Cited by 3
“114,115 Therefore, all these epigenetic processes create a complex network that controls gene expression, established lineage priming and orchestrates differentiation decisions in MPPs under steady state or pathological conditions.”
Is the philosopher’s stone to rejuvenate blood stem cells an epigenetic regulator?
Svendsen, A. F., & de Haan, G. (2022) · Nature Aging · doi:10.1038/s43587-022-00305-w · Cited by 2
Khanolkar, A., Liu, G., & Schneider, B. M. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813937 · Cited by 2
An Isoform-Specific RUNX1C–BTG2 Axis Governs AML Quiescence and Chemoresistance
Han, C., Zhang, Z., Crosse, E. I., Sajedi, S., Lü, B., Wang, X., Karma, S., Kostich, M. S., Rajendran, S. H., Udy, D. B., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0327 · Cited by 3
“The degradation of rRNA transcripts leads to reduced global protein synthesis, a hallmark of hematopoietic stem cell quiescence (56–58).”
Transcriptional Activation of Regenerative Hematopoiesis via Vascular Niche SensingPreprint
Itkin, T., Houghton, S., Schreiner, R. P., Lin, Y., Badwe, C. R., Voisin, V., Murison, A., Seyedhassantehrani, N., Kaufmann, K. B., García‐Prat, L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.27.534417 · Cited by 2
Loss of ING4 enhances hematopoietic regeneration in multipotent progenitor cells
Anderson, G. A., Hernandex, M., Alfaro-Quinde, C., Thompson, Z., Rodriguez, M., Binder, V., Taylor, A. M., & Kathrein, K. L. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316256 · Cited by 1
Reduced PU.1 Expression Collaborates with Tet2 Loss to Trigger Myeloid Leukemogenesis
Schleicher, W. E., & Pietras, E. M. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0100 · Cited by 1
Self-citationChen, Y.-H., Bi, T., Xu, M. Q., Lee, J., Lu, W. S., Zhuang, M., Velarde, A. M., McCurry, D., Yang, H., Alatrash, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.682671 · Cited by 1
“…may reflect a context-dependent role of MYC : in residual HSC/MPP-like populations, reduced MYC activity could (i) serve as an indicator of inflammatory stress ( 37, 38 ), and/or (ii) represent a distinct function of MYC in maintaining stemness or quiescence within MDS progenitors ( 39 ).”
Chavez, J. S., Rabe, J. L., Hernandez, G., Mills, T. S., Niño, K. E., Davizon-Castillo, P., & Pietras, E. (2021) · bioRxiv · doi:10.1101/2021.10.25.465758 · Cited by 1
Self-citationHematopoietic heterogeneity starts at the hemogenic endothelium
Lemerle, E., & Trompouki, E. (2023) · Cell Research · doi:10.1038/s41422-023-00806-2
Ahmad, K., Brahma, S., & Henikoff, S. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.03.020
Wang, T., Li, Y., Duan, Q., Wang, C., Wang, Y., & Hu, T. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101154
Impact of tumor on the cell cycle and differentiation of hematopoietic stem cells
Aktanova, A. A., Bykova, M. V., Skachkov, I., Denisova, V. V., & Pashkina, E. A. (2024) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2024.065
A bone marrow stromal secretome screen identifies semaphorin 3A as a regulator of hematopoiesisPreprint
Borger, D. K., Mitchell, S., Nakahara, F., Colombo, D., Torres, L. S., Garforth, S., Sidoli, S., Krijgsveld, J., Silberstein, L., Frenette, P. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.07.669162
Yu, H., Kim, Y. J., Chen, K., Liu, A. Z., Sunshine, M. J., & Signer, R. A. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.12.694052 · Cited by 1
“Ontogeny introduces profound shifts in HSC physiology, including changes in cell cycle behavior 17-22 , metabolic wiring 15,23-27 , lineage output 28-37 , and stress tolerance 5,16,38-43 .”
Additional file 1 of Reprogramming of 3D genome structure underlying HSPC development in zebrafish
He, M., Li, X., Xu, B., Lu, Y., Lai, J., Ling, Y., Liu, H., An, Z., Zhang, W., & Li, F. (2024) · Figshare · doi:10.6084/m9.figshare.26735595
Additional file 4 of Reprogramming of 3D genome structure underlying HSPC development in zebrafish
He, M., Li, X., Xu, B., Lu, Y., Lai, J., Ling, Y., Liu, H., An, Z., Zhang, W., & Li, F. (2024) · Figshare · doi:10.6084/m9.figshare.26735604
Additional file 2 of Reprogramming of 3D genome structure underlying HSPC development in zebrafish
He, M., Li, X., Xu, B., Lu, Y., Lai, J., Ling, Y., Liu, H., An, Z., Zhang, W., & Li, F. (2024) · Figshare · doi:10.6084/m9.figshare.26735598
Additional file 5 of Reprogramming of 3D genome structure underlying HSPC development in zebrafish
He, M., Li, X., Xu, B., Lu, Y., Lai, J., Ling, Y., Liu, H., An, Z., Zhang, W., & Li, F. (2024) · Figshare · doi:10.6084/m9.figshare.26735607
Ou, X., Wang, H., Tie, H., Liao, J., Luo, Y., Huang, W., Yu, R., Song, L., & Zhu, J. (2023) · Figshare · doi:10.6084/m9.figshare.23001896
Additional file 6 of Reprogramming of 3D genome structure underlying HSPC development in zebrafish
He, M., Li, X., Xu, B., Lu, Y., Lai, J., Ling, Y., Liu, H., An, Z., Zhang, W., & Li, F. (2024) · Figshare · doi:10.6084/m9.figshare.26735610
Additional file 3 of Reprogramming of 3D genome structure underlying HSPC development in zebrafish
He, M., Li, X., Xu, B., Lu, Y., Lai, J., Ling, Y., Liu, H., An, Z., Zhang, W., & Li, F. (2024) · Figshare · doi:10.6084/m9.figshare.26735601
Additional file 7 of Reprogramming of 3D genome structure underlying HSPC development in zebrafish
He, M., Li, X., Xu, B., Lu, Y., Lai, J., Ling, Y., Liu, H., An, Z., Zhang, W., & Li, F. (2024) · Figshare · doi:10.6084/m9.figshare.26735613
Aberrant oxidative metabolism selects for TET2 -deficient hematopoietic stem and progenitor cellsPreprint
Niño, K. E., Ademà, V., Gray, A. E., Cowan, C. M., Schleicher, W. E., Hosseini, M., Bennett, S. N., Patel, S. B., Moreira, S., Danis, E. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.28.707294
Self-citationPathogenic implication of the CD53 tetraspanin in immune and cancer cells
Lazo, P. A. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120142
Zhai, J., Li, X., Yin, M., Zhang, S., Liu, X., Wang, L., Wang, L., Wang, L., Ema, H., & Dong, F. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11100-0
Étude phénotypique et fonctionnelle des progéniteurs myéloïdes dans la drépanocytose
Serra, M. (2023) · theses.fr (ABES) · doi:10.70675/b36dbc93zd0f3z4c37za604z5321671ab3e3
Neutrophils in obesity: from expansion to dysfunction
Naranjo-Pinto, N., Alemán, O. R., & Rosales, C. (2026) · Clinical Immunology Communications · doi:10.1016/j.clicom.2026.05.005 · Cited by 1
Sojáková, D., Osadcha, T., Horváth, L., Husáková, J., Fejfarová, V., Sutoris, K., Jarošíková, R., & Dubský, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1850519
Interleukin-1-mediated inflammatory memory: Protective training or maladaptive tumor imprinting?
Xanthopoulou, D., Crespo, M., & Kalafati, L. (2026) · Seminars in Immunology · doi:10.1016/j.smim.2026.102047
Yang, C., Wang, T., Chai, Y., Wang, L., Wang, Y., Wang, W., Dong, F., & Suda, T. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00887-w · Cited by 1
Cell fate decision and lineage specification mechanisms in hematopoiesis
Lee, I., Earth, Y., & Kang, Y.-A. (2026) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2026.06.001
IL-1-mediated cancer-adapted hematopoiesis in aging and clonal hematopoiesis
Caiado, F., Gonullu, N. G., & Manz, M. G. (2026) · Seminars in Immunology · doi:10.1016/j.smim.2026.102055 · Cited by 1
Inflammatory Network Architecture Across Bone Marrow Failure: An Immune-Genetic Continuum
Beesetti, S. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl50689
Ünsal, Ş. E. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1943135
Metadata
- Authors
- Chavez, J. S., Rabe, J. L., Loeffler, D., Higa, K. C., Hernandez, G., Mills, T. S., Ahmed, N., Gessner, R. L., Ke, Z., Idler, B. M., Niño, K. E., Kim, H., Myers, J. R., Stevens, B. M., Davizon-Castillo, P., Jordan, C. T., Nakajima, H., Ashton, J., Welner, R. S., Schroeder, T., DeGregori, J., & Pietras, E. M.
- Affiliations
- University of Colorado Anschutz (US)
- ETH Zurich (CH)
- University of Rochester (US)
- Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 9
- Yokohama City University (JP)
- University of Alabama at Birmingham (US)
- Corresponding author
- Pietras, Eric M.
- ORCID
- Chavez, James S.
- Rabe, Jennifer L.
- Loeffler, Dirk
- Higa, Kelly C.
- Hernandez, Giovanny
- Mills, Taylor S.
- Ahmed, Nouraiz
- Gessner, Rachel L.
- Ke, Zhonghe
- Idler, Beau M.
- Niño, Katia E.
- Kim, Hyunmin
- Myers, Jason R.
- Stevens, Brett M.
- Davizon-Castillo, Pavel
- Jordan, Craig T.
- Nakajima, Hideaki
- Ashton, John
- Welner, Robert S.
- Schroeder, Timm
- DeGregori, James
- Pietras, Eric M.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2021-04-15
- Volume
- 218
- Issue
- 6
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC8056754
- OpenAlex
- W3156682036
- Semantic Scholar
- 0d4c6e501e7ab1ae5a80340cc5aac0dc7be1a2d9
- Cited by
- 91
- References
- 112
- Citations by year
- 2026: 16 · 2025: 12 · 2024: 16 · 2023: 20 · 2022: 16 · 2021: 10
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by-nc-nd)
- Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by-nc-sa)
- ETH Zürich Research Collection
- Funders
- National Institutes of Health (R01 DK119394, K01 DK098315, R01 AG067584, F31 HL138754, F30 CA210383, T32 AG000279)
- Boettcher Webb-Waring Early Career Investigator Award
- Cleo Meador and George Ryland Scott Endowed Chair in Hematology
- Swiss National Science Foundation (179490)
- National Science Foundation
- University of Colorado Cancer Center
- National Cancer Institute (P30 CA046934)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- PU.1, hematopoietic stem cells, HSC quiescence, HSC expansion, interleukin-1, inflammation, transcriptional repression, HSC homeostasis, innate immune signaling
- MeSH terms
- Proto-Oncogene Protein Spi-1, Animals, Cell Cycle, Cell Differentiation, Hematopoietic Stem Cells, Homeostasis, Immunity, Innate, Inflammation, Mice, Inbred C57BL, Proto-Oncogene Proteins, Stress, Physiological, Trans-Activators, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.